Delivery Order SPE2DB22D2108-SPE2DB25FU5QM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,846.11 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive, firm fixed-price delivery order, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, represents a pharmaceutical supply transaction under the company's existing contract vehicle with DLA. The products will be delivered to AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,092.72 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued on September 8, 2025, and represents a firm fixed-price pharmaceutical supply transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a primary pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $3,284.26 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract was awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, and utilizes firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,997.60 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,903.58 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price procurement with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a $3,487.28 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 9, 2025. This firm fixed-price delivery order, awarded September 8, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5QMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,204.12 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. Issued on August 27, 2025, this firm fixed price delivery order is scheduled for completion by August 28, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under a larger contract vehicle and reflects the company's role as a critical pharmaceutical distributor supporting federal medical procurement needs. This delivery order is issued as a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a wide range of medications and medical supplies to support military healthcare programs and other federal health systems worldwide. The insulin procurement exemplifies the company's role in fulfilling critical pharmaceutical requirements for the Defense Health Agency and military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 8/27/25 |